explor
subsit
via
modif
p
methylen
biphenyl
moieti
thiolbas
metalloproteas
inhibitor
led
improv
select
versu
ace
nep
maintain
potent
inhibit
dampen
reninangiotensin
signal
cascad
ra
proven
invalu
treatment
cardiovascular
diseas
drug
inhibit
famili
dicarboxymetallopeptidas
angiotensinconvert
enzym
ace
ec
famili
aspart
proteas
renin
ec
well
antagon
g
proteincoupl
angiotensin
receptor
ii
improv
hypertens
dual
ace
metalloproteas
neutral
endopeptidas
neprilysin
nep
ec
inhibit
also
explor
treatment
high
blood
pressur
recent
new
member
ra
famili
monocarboxymetallopeptidas
angiotensinconvert
enzym
identifi
membraneassoci
secret
metalloproteas
express
heart
kidney
test
intestin
lung
highest
homolog
ace
implic
cardiovascular
diseas
kidney
diseas
obes
lung
diseas
angiotensin
receptor
agonist
angiotensin
ii
substrat
convert
angiotensin
ma
receptor
agonist
angiotensin
respect
reveal
role
ra
regul
moreov
mice
studi
reveal
role
proteas
cardiac
contractil
angiotensin
iiinduc
hypertens
heart
failur
furthermor
male
mice
femal
mice
also
develop
glomerulosclerosi
kidney
exact
role
reninangiotensin
system
ra
still
need
clarifi
addit
mice
resist
weight
gain
high
fat
diet
final
primari
receptor
sever
acut
respiratori
syndrom
sar
corona
viru
entri
cell
mice
resist
sar
corona
viru
infect
limit
space
author
refer
interest
reader
recent
review
ham
et
al
comprehens
summari
physiolog
patholog
mani
put
role
small
molecul
modul
enzym
activ
could
util
help
defin
physiolog
function
enzym
although
small
molecul
induc
proteas
difficult
discov
activ
could
provid
insight
function
substrat
process
similarli
inhibitor
could
also
shed
light
role
proteinspeptid
activatesdegrad
effort
discov
inhibitor
recent
disclos
millennium
pharmaceut
research
report
discoveri
revers
subnanomolar
inhibitor
ic
nm
deriv
micromolar
lead
addit
dyax
research
identifi
micromolar
peptid
inhibitor
use
phage
display
librari
approach
includ
amino
acid
cyclic
peptid
ic
nm
furthermor
pharmacophorebas
virtual
screen
approach
commerci
databas
identifi
sever
micromolar
inhibitor
best
inhibitor
ic
nm
final
research
univers
florida
also
util
virtual
screen
exercis
nci
databas
identifi
n
aziridineethanamin
naae
ic
nm
irrevers
inhibitor
recent
employ
direct
screen
set
metalloproteas
inhibitor
glaxosmithklin
compound
collect
gsk
research
report
identif
known
acenep
inhibitor
potent
inhibitor
zinc
metalloproteas
structureact
studi
subsit
led
identif
p
modifi
thiol
acid
potent
inhibitor
k
app
nm
improv
select
versu
ace
k
app
nm
nep
k
app
nm
also
inhibit
metalloproteas
carboxypeptidas
cpa
ec
k
app
nm
specul
select
could
improv
exploit
potenti
differ
subsit
ace
nep
structureact
relationship
p
posit
inhibitor
explor
goal
maintain
potenc
reduc
ace
nep
inhibitori
activ
thiol
analog
prepar
depict
scheme
amin
hydrochlorid
coupl
acid
situ
activ
azahydroxybenzotriazol
ester
via
carbodiimid
produc
fulli
protect
amid
hydrolysi
thioacet
methyl
ester
lithium
hydroxid
afford
thiol
acid
amin
hydrochlorid
commerci
avail
remain
amin
hydrochlorid
prepar
depict
scheme
commerci
avail
amino
acid
convert
correspond
methyl
ester
thionyl
chlorid
methanol
reflux
result
amin
hydrochlorid
protect
tertbutyl
carbam
ditertbutyl
dicarbon
suzuki
cross
coupl
obromid
x
br
phenyl
boron
acid
afford
obiphenyl
deriv
acid
catalyz
cleavag
carbam
gave
obiphenyl
amin
hydrochlorid
mphenol
x
oh
convert
triflat
trifluoromethanesulfon
anhydrid
coupl
via
suzuki
protocol
phenyl
boron
acid
provid
fulli
protect
mbiphenyl
deriv
subsequ
hydrolysi
amin
mask
group
gave
mbiphenyl
amin
hydrochlorid
obromid
x
br
convert
ophenol
x
oh
via
palladiummedi
transform
bromid
boron
ester
oxid
boron
phenol
hydrogen
peroxid
employ
modifi
ullmann
ether
synthesi
protocol
ophenol
mphenol
coupl
phenyl
boron
acid
afford
oand
mdiaryl
ether
acid
uncloak
tertbutyl
carbonyl
protect
group
produc
phenyl
ether
final
util
williamson
ether
synthesi
ophenol
mphenol
commerci
avail
pphenol
alkyl
variou
benzyl
bromid
give
fulli
mask
benzyl
aryl
ether
unmask
carbam
afford
amin
hydrochlorid
structureact
relationship
p
analog
depict
tabl
complet
remov
p
substitu
analog
result
larg
decreas
k
app
nm
nep
k
app
nm
inhibitori
activ
potenti
reduct
van
der
waal
interact
absenc
p
side
chain
well
entrop
gain
increas
rotat
freedom
acid
could
account
decreas
potenc
contrast
chang
littl
affect
ace
k
app
nm
cpa
k
app
nm
alaninederiv
analog
k
app
nm
nep
k
app
nm
decreas
rotat
freedom
recov
inhibitori
activ
lost
upon
remov
p
group
dramat
chang
activ
versu
ace
k
app
nm
cpa
k
app
nm
phenylalanin
tyrosin
deriv
k
app
nm
k
app
nm
equipot
inhibitor
methylen
pbiphenyl
analog
similar
ace
k
app
nm
k
app
nm
nep
k
app
k
app
nm
activ
well
contrast
benzyl
deriv
potent
inhibitor
cpa
k
app
nm
k
app
nm
sinc
mani
good
cpa
substrat
contain
p
phenylalanin
residu
increas
cpa
inhibit
surpris
decid
explor
bulki
p
substitu
goal
improv
potenc
andor
select
analog
sinc
bulki
methylen
biphenyl
p
moieti
readili
accommod
enzym
impli
larg
subsit
although
amethylen
naphthyl
bmethylen
naphthyl
deriv
k
app
nm
k
app
nm
also
potent
inhibitor
select
versu
ace
k
app
nm
k
app
nm
cpa
k
app
nm
k
app
nm
still
retain
substanti
inhibitori
activ
nep
k
app
nm
k
app
nm
contrast
pphenyl
phenylalanin
deriv
ophenyl
phenylalanin
analog
k
app
nm
order
magnitud
less
potent
inhibitor
substitut
also
reduc
ace
k
app
nm
nep
k
app
nm
inhibit
alter
cpa
potenc
k
app
nm
contrast
methylen
mbiphenyl
deriv
k
app
nm
equipot
inhibitor
pderiv
despit
branch
phenyl
moieti
differ
angl
offer
clear
select
advantag
ace
k
app
nm
nep
k
app
nm
cpa
k
app
nm
versu
although
larg
biphenyl
deriv
fairli
rigid
toler
subsit
thu
bulkier
p
group
explor
pphenoxi
phenylalanin
deriv
k
app
nm
k
app
nm
k
app
nm
retain
good
potenc
inhibit
select
versu
ace
k
app
nm
k
app
nm
k
app
nm
cpa
k
app
nm
k
app
nm
k
app
nm
despit
alter
branch
termini
contrast
nep
select
differ
ophenyloxi
analog
k
app
nm
select
versu
nep
mphenoxi
analog
k
app
nm
pphenoxi
analog
k
app
nm
nep
select
respect
surprisingli
extend
pbenzyloxi
phenylalanin
deriv
k
app
nm
k
app
nm
k
app
nm
also
well
toler
subsit
addit
maintain
good
select
versu
ace
k
app
nm
k
app
nm
k
app
nm
cpa
k
app
nm
k
app
nm
k
app
nm
contrast
phenyloxi
analog
pbenzyl
analog
k
app
nm
quit
select
versu
nep
obenzyloxi
analog
k
app
nm
mbenzyloxi
analog
k
app
nm
less
select
respect
methylen
ophenoxyphenyl
deriv
methylen
pbenzyloxyphenyl
analog
potent
select
inhibitor
latter
inhibitor
readili
deriv
cheap
natur
amino
acid
tyrosin
therefor
fluorin
deriv
inhibitor
prepar
goal
maintain
potenc
select
block
potenti
metabol
site
nake
phenyl
ring
hope
electron
withdraw
group
would
steric
imped
metabol
also
electron
deactiv
aryl
ring
oxid
monoand
difluoro
analog
k
app
nm
k
app
nm
k
app
nm
potent
inhibitor
good
select
tyrosin
deriv
select
analog
separ
k
app
ace
k
app
nm
nep
k
app
nm
cpa
k
app
nm
contrast
inhibit
fluoro
deriv
larger
trifluoromethyl
deriv
k
app
nm
k
app
nm
substanti
less
potent
inhibitor
like
larger
p
substitu
clash
residu
make
subsit
vitro
drug
metabol
pharmacokinet
assay
perform
help
predict
vivo
oral
bioavail
pharmacokinet
thiol
although
inhibitor
conform
lipinski
rule
madindarbi
canin
kidney
mdck
assay
reveal
inhibitor
class
poor
moder
passiv
cell
permeabl
p
app
nm
sinc
mani
dipeptid
absorb
activ
transport
mechan
repres
thiolbas
inhibitor
dose
oral
rat
despit
poor
predict
cell
permeat
limit
absorpt
f
agreement
mdck
assay
model
thiol
dock
activ
site
base
recent
millennium
xray
crystal
structur
shown
figur
provid
insight
p
sar
thiol
seri
termin
carboxyl
inhibitor
accept
hydrogen
bond
imidazol
form
salt
bridg
guanidin
arg
also
amid
nitrogen
inhibitor
donat
hydrogen
atom
carbonyl
pro
amid
carbonyl
accept
hydrogen
atom
tyr
moreov
addit
normal
ligand
imidazol
nitrogen
carboxyl
glu
activ
site
zinc
coordin
thiol
inhibitor
furthermor
p
secbutyl
group
inhibitor
form
van
der
waal
interact
pocket
compos
thr
phe
tyr
arg
greasi
p
side
chain
form
signific
lipophil
interact
quit
larg
channel
compos
lengthwis
canal
two
subdomain
includ
residu
phe
thr
glu
gln
although
sever
residu
pocket
hydrophil
polar
group
either
involv
hydrogen
bond
enzym
residu
orient
away
pocket
maintain
lipophil
natur
subsit
base
model
portion
p
substitu
hypothes
occupi
differ
part
larg
pocket
p
side
chain
carboxyl
inhibitor
cocrystal
contrast
shown
figur
model
thiol
dock
activ
site
reveal
ophenyloxi
p
group
occupi
differ
part
subsit
substitu
analog
ophenyloxi
p
moieti
fit
portion
subsit
compos
met
pro
thr
trp
asp
thr
tyr
leu
asn
ly
asp
disulfid
pair
cy
cy
thu
ophenyloxi
p
moieti
bind
similarli
p
side
chain
millennium
carboxyl
inhibitor
cocrystal
interact
inhibitor
similar
analog
thu
two
model
help
explain
diverg
p
sar
sinc
larg
fork
subsit
toler
substitu
differ
branch
point
summari
variat
substitu
p
posit
seri
athiol
amidebas
inhibitor
result
discoveri
potent
inhibitor
good
ace
nep
select
inhibitor
contain
pmethylen
aryl
tyrosin
p
moieti
like
select
inhibitor
addit
ophenyloxi
phenylalanin
analog
also
potent
select
inhibitor
analog
may
prove
use
defin
role
play
ra
cascad
